NCT01235975CompletedPhase 3
Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 400
- Locations
- 2
- Primary Endpoint
- Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY)
Study Overview
Brief Summary
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 56 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects who the investigator believes can and will comply with the requirements of the protocol
- •A male or female 56 years of age or older at the time of the vaccination.
- •Written informed consent obtained from the subject.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Non-child-bearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.
Exclusion Criteria
- •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational product.
- •Extended administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination. Inhaled and topical steroids are allowed.
- •Any contra-indication to intramuscular and /or subcutaneous injection.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination and ending 30 days after vaccination. (Vaccination with inactivated influenza vaccines, including H1N1, is allowed at any time during the study as per local recommendations).
- •Previous vaccination with meningococcal serogroups A, C, W-135 and Y polysaccharide vaccine within 5 years prior to vaccination.
- •Previous vaccination at any time with meningococcal serogroups A, C, W-135 and Y polysaccharide conjugate vaccine.
- •Previous vaccination with tetanus toxoid containing vaccine within 5 years prior to vaccination.
- •History of meningococcal disease due to serogroups A, C, W-135 or Y.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Family history of congenital or hereditary immunodeficiency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •History of neurological disorders and seizures
- •History of Guillain-Barre syndrome.
- •Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests.
- •Acute disease and/or fever at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine/product or planned administration during the study period.
- •Pregnant or lactating female.
- •Current chronic alcohol consumption and/or drug abuse.
Arms & Interventions
Group A
Experimental
Intervention: Meningococcal vaccine GSK 134612 (Biological)
Group B
Active Comparator
Intervention: MencevaxACWY TM (Biological)
Outcomes
Primary Outcomes
Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY)
Time Frame: One month after vaccination (Month 1)
Vaccine response for serum bactericidal assay using rabbit complement (rSBA) antibodies against Neisseria meningitides serogroups A, C , W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) was defined as: for initially seronegative subjects \[rSBA titer below (\<) 1:8\], post-vaccination rSBA titer greater than or equal to (≥) 1: 32; for initially seropositive subjects with rSBA titer between 1:8 and 1:128, at least four-fold increase in rSBA titer from pre to post vaccination; and for initially seropositive subjects with rSBA titer ≥1:128, at least two-fold increase in rSBA titer from pre to post vaccination.
Secondary Outcomes
- rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers(At Day 0 and Month 1)
- Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations ≥ the Cut-off Value(At Day 0 and Month 1)
- Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations ≥ the Cut-off Value(At Day 0 and Month 1)
- Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations(At Day 0 and Month 1)
- Number of Subjects With Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations ≥ the Cut-off Value(At Day 0 and Month 1)
- Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations(At Day 0 and Month 1)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(Within 4 days (Day 0 to 3) post-vaccination)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(Within 4 days (Day 0 to 3) post-vaccination)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(Within 31 days (Day 0 to 30) after vaccination)
- Number of Subjects With Serious Adverse Events (SAEs)(Within 31 days (Day 0 to 30) after vaccination)
- Number of Subjects With New Onset Chronic Illnesses (NOCI)(Within 31 days (Day 0 to 30) after vaccination)
- Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ the Cut-off Value(At Day 0 and Month 1)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and ToddlersMeningococcal InfectionNCT01340898GlaxoSmithKline753
Completed
Phase 3
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesInfections, MeningococcalMeningococcal VaccinesNCT01144663GlaxoSmithKline2,095
Completed
Phase 2
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of AgeInfections, MeningococcalNCT03652610GlaxoSmithKline996
Completed
Phase 2
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®PoliomyelitisMeningococcal MeningitisPertussisTetanusDiphtheriaNCT00355121Sanofi882
Completed
Phase 2
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.Infections, MeningococcalNCT00471081GlaxoSmithKline385